Medical CAS 30123-17-2 Tianeptine Sodium Raw Materials Tianeptine Sodium

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Tianeptine sodium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Tianeptine Sodium
• Name: Tianeptine Sodium Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Density: 1.38
• Melting Point: 1800c
• Boiling Point: 609.2c
• Mf: C21h24cln2nao4s
• MW: 458.933
• CAS: 30123-17-2
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Tianeptine sodium
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

Medical CAS 30123-17-2 Tianeptine sodium Raw Materials Tianeptine sodium

Product Description

Product Details

Product Name	Tianeptine sodium
Appearance	Tianeptine sodium Powder
Assay	>99%
MW	458.933
MF	C21H24ClN2NaO4S
Density	1.38
Melting Point	1800C

Tianeptine sodium has structural similarities to the tricyclic antidepressants, but it has different pharmacological properties. Tianeptine is a selective serotonin reuptake enhancer (SSRE), opposite to the action of SSRIs. One review points to the cancellative effects of tianeptine and fluoxetine coadministration on serotonin reuptake. Another suggests that long-term administration of tianeptine has no effect on serotonin pathways. Tianeptine enhances the extracellular concentration of dopamine in the nucleus accumbens and modulates the D2 and D3 dopamine receptors. There is also action on the NMDA and AMPA receptors.

Application&Function

Tianeptine sodium is a drug used primarily in the treatment of major depressive disorder, although it may also be used to treat asthma or irritable bowel syndrome. Chemically it is a tricyclic antidepressant (TCA), but it has different pharmacological properties than typical TCAs as recent research suggests that tianeptine produces its antidepressant effects through indirect alteration of glutamate receptor activity (i.e., AMPA receptors and NMDA receptors) and release of BDNF, in turn affecting neural plasticity.

Specification